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Chapter 3: Interleukin-6 receptor and its ligand interleukin-6 are opposite markers 
for survival and infiltration with mature myeloid cells in ovarian cancer
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An increased level of interleukin-6 (IL-6) in epithelial ovarian cancer (EOC) is cor-
related with a worse prognosis. IL-6 stimulates tumor-growth and –inflammation. 
We investigated the intricate interaction between the IL-6 signaling pathway and tu-
mor-infiltrating myeloid cells to determine their prognostic impact in EOC. 160 EOC 
samples were analyzed for the expression of IL-6, its receptor (IL-6R) and down-
stream signaling via pSTAT3 by immunohistochemistry. Triple color immunofluores-
cence confocal microscopy was used to identify myeloid cell populations by CD14, 
CD33, and CD163. The relationship between these markers, tumor-infiltrating im-
mune cells, clinical-pathological characteristics and survival was investigated. EOC 
displayed a dense infiltration with myeloid cells, in particular of the CD163+ type. 
The distribution pattern of all myeloid subtypes was comparable among the differ-
ent histological subtypes. Analysis of the tumor cells revealed a high expression of 
IL-6R in 15% and of IL-6 in 23% of patients. Interestingly, tumors expressing IL-6 or 
IL-6R formed two different groups. Tumors with a high expression of IL-6R displayed 
low mature myeloid cell infiltration and a longer disease-specific survival (DSS), es-
pecially in late stage tumors. High expression of IL-6R was an independent prog-
nostic factor for survival by multivariate analyses (hazard ratio=0.474, p=0.011). In 
contrast, tumors with high epithelial IL-6 expression displayed a dense infiltration 
of mature myeloid cells and were correlated with a shorter DSS. Furthermore, in 
densely CD8 T-cell infiltrated tumors, the ratio between these lymphoid cells and 
CD163+ myeloid cells was predictive for survival. Thus, IL-6 and IL-6R are opposite 
markers for myeloid cell infiltration and survival.










Epithelial ovarian cancer (EOC) remains a silent killer among women. Since 
most patients are asymptomatic until the disease has metastasized, two-thirds are 
diagnosed with advanced stage disease. Conventional treatment (surgery com-
bined with chemotherapy) results are poor; 75% of the patients with advanced dis-
ease develop recurrences, causing approximately 60-80% of patients to die within 
5 years of initial diagnosis (1–3). EOC consists of distinct histological subtypes. The 
most common subtype is serous carcinoma, which accounts for about 70% of EOC. 
Other subtypes are endometrioid, mucinous and clear cell, of which the latter is 
associated with a worse prognosis than all the other subtypes (4,5).
EOC are infiltrated by a variety of immune cells (6–10). There are strong 
correlations between the number and type of tumor-infiltrating lymphocytes (TILs) 
and a favorable clinical outcome (9,10). The spontaneous tumor-specific immune 
response, however, is weak and counteracted by local immunosuppressive cells, 
like regulatory T cells (Treg), preventing the infiltration or function of immune ef-
fector cells. In addition to TILs, tumor-infiltrating myeloid cells (TIMs) are present 
in EOC. Tumor-associated macrophages (TAMs) and myeloid-derived suppressor 
cells (MDSCs) originate from myeloid precursors in the blood and undergo specific 
differentiation depending on cues in the local tumor microenvironment. They can 
roughly be divided into two distinct polarization states: the classically activated type 
1 macrophages (M1), which are tumoricidal and produce interleukin-12 (IL-12), as 
well as the alternative activated type 2 macrophages (M2), which produce IL-10 and 
sabotage antitumor immunity. The presence of M2 macrophages in ovarian tumors 
is correlated with poor prognosis (11,12). MDSCs are a heterogeneous population 
of cells that expand during cancer progression and have a remarkable ability to sup-
press T-cell responses, albeit that their mode of action is different from Treg (13).
IL-6 is a major mediator of cancer-related inflammation by stimulating in-
flammatory cytokine production, tumor growth, tumor angiogenesis, and tumor 
macrophage infiltration in ovarian cancer (14–17). Notably, the differentiation of 
both M2 macrophages and MDSCs can be mediated by IL-6 (13,16,18). However, 
the intricate interactions between IL-6 and tumor infiltration by myeloid cells in 
ovarian cancer are not well understood.
Aiming to elucidate these interactions, we studied the expression of IL-6, IL-6 re-
ceptor (IL-6R) and phosphorylated signal transducer and activator of transcription 3 
(pSTAT3), important mediators in the IL-6 signaling pathway, as well as the number 
and type of infiltrating myeloid cells present in EOC. We determined the relation-
ship between these markers, and their prognostic or therapeutic impact in a unique 
cohort of EOC (9).
Here, we demonstrate that the expression of IL-6 and its receptor are oppo-
site markers for survival and infiltration with mature myeloid cells in ovarian cancer.











Since 1985, the Department of Gynecological Oncology of the University 
Medical Center Groningen (UMCG) prospectively stores all clinicopathologic and 
follow-up data of malignant EOC patients in a digital database. Primary treatment of 
all patients consisted of surgery, followed (when possible) by adjuvant chemother-
apeutic treatment. Since 1995, platinum-based chemotherapy was supplemented 
with taxanes. Patients were surgically staged according to International Federation 
of Gynecology and Obstetrics (FIGO) classification (19). Optimal and suboptimal 
debulking was defined as the largest residual tumor lesions having a diameter of, 
respectively, <2 cm or ≥2 cm. Histology of all tumors was determined according to 
World Health Organization criteria (20). Follow-up was updated in July 2009. For 
the present study, relevant data from our digital database of all patients were trans-
ferred into a separate anonymous database, in which patient identity was protected 
by unique patient codes. According to Dutch law, no approval from our institutional 
review board was needed.
 
Tissue Micro-Arrays
Tumor samples from 361 patients were collected on a tissue micro-array 
(TMA). This TMA contained primary ovarian tumor tissue of 270 patients obtained 
before chemotherapeutic treatment. Patients with borderline or non-epithelial tu-
mors were excluded. For this study, a cohort with the most recently treated patients 
(N=160) was selected for analysis. The TMAs were constructed as previously de-
scribed (9,21,22). In brief, four representative cores with a diameter of 0.6 mm were 
taken out of paraffin-embedded tissue blocks using a tissue microarrayer (Beecher 
Instruments, Silver Spring, MD, USA) and were placed on a recipient paraffin block. 
From each TMA block, sections of 4 µm were cut and applied to APES-coated slides. 
The presence of tumor in the arrayed samples was confirmed by H&E staining.
 
Immunohistochemical staining
TMA sections were deparaffinized and rehydrated using xylene and grad-
ed concentrations of ethanol. Heat-induced antigen retrieval was performed in ci-
trate buffer (10 mM citrate, pH 6.0). Endogenous peroxidase was blocked in a 0.3% 
H2O2 solution, after which sections were incubated with primary antibodies over-
night at 4°C; rabbit polyclonal IL-6 antibody (1:400, Abcam), rabbit polyclonal to 
IL-6Rα (1:800, Santa Cruz Biotechnology), and rabbit monoclonal pSTAT3 antibody 
(1:150, Cell Signaling Technology, clone Tyr705). The antibodies were detected us-
ing HRP-labeled secondary (goat anti-rabbit) and tertiary (rabbit anti-goat) antibod-
ies for 30 minutes at RT (1:100, DAKO,), and visualized with 3,3-diaminobenzidine. 
Hematoxylin was used for counterstaining.
 









All staining patterns were scored independently by two observers, who had 
no prior knowledge of clinicopathological information. To achieve good concor-
dance with whole tissue slides, minimally two cores containing at least 20% tumor 
epithelium had to be present on the TMA for a sample to be selected for further 
analysis (21). IL-6 expression in stroma and IL-6R staining were scored according 
to the method of Ruiter et al (23). The intensity of the staining was scored as 0 
(absent), 1 (weak), 2 (positive), or 3 (strong expression). The percentage of positive 
tumor cells was grouped as 0 (0%), 1 (1-5%), 2 (5-25%), 3 (25-50%), 4 (50-75%), and 
5 (75-100%). The sum of these two scores was divided by the number of evaluated 
cores per tumor, which was subsequently grouped into no/weak expression (0-2), 
medium expression (3-6), and high expression (7-8). IL-6R expression in stroma was 
scored in 4 intensity categories: none, weak, medium, or strong staining. Patients 
were categorically defined as either having positive or negative expression for IL-6 
or pSTAT3 within the tumor epithelium, with the latter localized to the nucleus.
 
Immunofluorescent staining
Characterization of tumor-infiltrating myeloid cells (TIM) was carried out 
with triple immunofluorescent staining as described previously (24). Briefly, after 
deparaffinization and rehydration of the 4-μm tissue sections, heat-mediated an-
tigen retrieval with a 1 mmol/L EDTA solution (pH 9.0) was performed. A mixture 
containing primary antibodies anti-CD33 (1:50, mouse-IgG2b, clone PWS44, Leica 
Microsystems B.V.), anti-CD14 (1:100, mouse-IgG2a, clone 7, Leica Microsystems 
B.V.) and anti-CD163 (1:400, mouse-IgG1, Clone 10D6, Leica Microsystems B.V.) was 
applied to the tissue sections overnight at room temperature. The next day, a mix-
ture of fluorescently labeled secondary antibodies (goat anti-mouse IgG2b-Alexa 
Fluor 546, goat anti-mouse IgG2a-Alexa Fluor 488 and goat anti-mouse IgG1-Alexa 
Fluor 647; Molecular Probes) was used to detect primary antibody binding. Images 
were captured with a confocal laser-scanning microscope (Zeiss LSM 510) in a mul-
titrack setting. Epithelial tumor cell nests and stromal areas were measured using 
the Zeiss LSM Image Examiner. Myeloid subsets were manually counted in all repre-
sentative images for either tumor epithelium, stroma, or both and were presented 
as the number of cells per mm2.
 
Statistical Analysis
Statistical analysis was performed using Statistical Package for the Social 
Sciences [SPSS Statistics] 20 software package for Windows (SPSS Inc.). For all tests, 
p-values <0.05 were considered significant and all p-values were tested two-sided. 
Disease-specific survival (DSS) was defined as the time period from date of surgery 
until death due to ovarian cancer or last follow-up. DSS was calculated using the 
Kaplan Meier method. Survival differences between groups were assessed using 
the Log Rank test. Variables that were significantly associated with DSS in the uni-








variate analyses were entered into a multivariate analysis. For this purpose, Cox 
proportional hazards models, stratified for type of chemotherapy, were used. The 
χ2 test was used to associate markers of the IL-6 pathway, myeloid cell populations, 
lymphoid cell populations, and clinicopathological parameters. Spearman’s correla-
tion was applied to calculate correlation between the myeloid cell populations. The 
Mann Whitney U test with Bonferroni correction for multiple comparisons was used 
to determine differences in infiltration of myeloid cells and IL-6R expression be-
tween patient populations.
Unsupervised hierarchical clustering was performed as described previous-
ly (25) using complete-linkage and Euclidian distance in the function ‘heatmap’ of 
the ‘stats’ package in R. (Development Core Team, a language and environment for 
statistical computing, reference index version 2.14.0. 2005. Foundation for Statisti-
cal Computing, Vienna, Austria).
 
 











 Sufficient formalin-fixed paraffin embedded tumor tissue was available 
from 160 ovarian cancer patients. Clinicopathological characteristics of patients are 
summarized in Table 1. Half of the patients presented with serous histology and/or 
high-grade disease. The majority of patients presented with late stage (FIGO stage 
III, IV) disease. The median disease-specific survival (DSS) was 51.0 months (95% CI 
32.9-69.1, estimated five-year DSS rate 46.1%). Of the patients treated with chemo-
therapeutics, 77.5% received a platinum-based regimen of whom 59.4% received 
this chemotherapeutic drug combined with taxane. However, 24 patients did not 
receive chemotherapy, as 15 patients presented with FIGO stage I and the remain-
ing patients were either unfit or unwilling to receive chemotherapy.
 
Expression of markers of the IL-6 signaling pathway
 First we evaluated the expression of IL-6, the IL-6R, and pSTAT3 in EOC with-
in the tumor epithelium and stroma (Table 2A). Representative staining patterns of 
the markers are depicted in Figure 1. IL-6 expression was found in the tumor epithe-
lium of 23.0% of patients, while 46.1% of the patients showed stromal expression. 
Expression of IL-6 in tumor epithelium was not correlated with stromal expression 
of IL-6 (Table 2B). The IL-6R was very abundant on the tumor epithelium of the pa-
tients in this cohort with medium expression in 69.6% and high expression in 15.2% 
of all patients. Stromal expression of IL-6R was often absent or weak (87.1%), how-
ever, when present (13%), it was positively correlated with the expression of IL-6R 
on tumor epithelium (p<0.001; Table 2B). There was no correlation between the ex-
pression of IL-6 and the expression of IL-6R within the tumor epithelium or stroma. 
The expression of pSTAT3 in tumor cells was found in 20% of the tumors, which was 
lower than the medium and high expression of IL-6R in tumor epithelium. Statistical 
analyses revealed that the expression patterns of pSTAT3 and the different markers 
did not correlate to one another.
 
Markers of the IL-6-signaling pathway in different EOC subtypes and disease 
stages
 The entire cohort analyzed for the markers of the IL-6 signaling pathway 
comprises a number of different histological epithelial ovarian tumor types (Ta-
ble 1). In order to analyze subtype-specific associations, differences in expression 
of these markers were examined. A high expression of IL-6R was more frequently 
found in mucinous and endometrioid subtypes than in tumors with serous histology 
(p=0.032) (Table 2A). However, the expression levels of IL-6 did not differ between 
the different subtypes. Furthermore, we determined whether expression varied be-
tween early (FIGO I/II) and late (FIGO III/IV) FIGO stages. Early stage disease showed 
relatively more high epithelial expression of the IL-6R (p=0.035), which is in line 








with the fact that the great majority of the early stage tumors were among the 
mucinous and endometrioid tumors (Supplementary Table S1). Late stage tumors 























Table	  1	  Clinicopathological	  characteristics	  and	  survival	  
data	  of	  the	  160	  patients	  included	  in	  TMA	  analysis	  
	  	   N	  (%)	   	  	   	  	   	  	  
Age	  (years)	   	  	   	  	  
	  
	  	  
Mean	  (SD)	   57.99	  (12.768)	  
	   	   	  
	   	   	   	   	  DSS	  (months)	  
	   	   	   	  Median	  (95%	  CI)	   51.0	  (32.9-­‐69.1)	  
	   	   	  
	   	   	   	   	  FIGO	  stage	  
	   	   	   	  Stage	  I	   41	  (25.6%)	  
	   	   	  Stage	  II	   13	  (8.1%)	  
	   	   	  Stage	  III	   83	  (51.9%)	  
	   	   	  Stage	  IV	   23	  (14.4%)	  
	   	   	  
	   	   	   	   	  Tumor	  type	  
	   	   	   	  Serous	   80	  (50.0%)	  
	   	   	  Mucinous	   21	  (13,1%)	  
	   	   	  Endometrioid	   23	  (14.4%)	  
	   	   	  Clear	  Cell	   11	  (6.9%)	  
	   	   	  Adenocarcinoma	   7	  (4.4%)	  
	   	   	  Mixed	  Tumors	   12	  (7.5%)	  
	   	   	  Other	   6	  (3.7%)	  
	   	   	  
	   	   	   	   	  Tumor	  grade	  
	   	   	   	  Grade	  I	   25	  (15.6%)	  
	   	   	  Grade	  II	   52	  (32.5%)	  
	   	   	  Grade	  III	   70	  (43.8%)	  
	   	   	  Undifferentiated	   7	  (4.4%)	  
	   	   	  Missing	   6	  (3.8%)	  
	   	   	  
	   	   	   	   	  Residual	  disease	  
	   	   	   	  <2cm	   98	  (61.3%)	  
	   	   	  >=2cm	   50	  (31.2%)	  
	   	   	  Missing	   12	  (7.5%)	  
	   	   	  
	   	   	   	   	  Chemotherapy	  
	   	   	   	  No	  chemotherapy	   24	  (15.0%)	  
	   	   	  Platinum-­‐containing	   29	  (18.1%)	  
	   	   	  Platinum	  &	  taxane	  containing	   95	  (59.4%)	  
	   	   	  Other	  regimen	   6	  (3.8%)	  
	   	   	  Unknown	   6	  (3.8%)	   	   	   	  
DSS	  =	  disease-­‐specific	  survival;	  FIGO	  =	  International	  Federation	  	  
of	  Gynaecology	  and	  Obstetrics.	  
	   	  























































































































































	  	  	  







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table	  2B	  p-­‐values	  of	  correlation	  markers	  of	  IL-­‐6	  signaling	  pathway	  with	  









































Tumor	  epithelium1,2	   	  	   	  	   	  	   	  	   	  	  
CD14+CD33-­‐CD163-­‐	   -­‐.000	   -­‐.170	   -­‐.477	   -­‐.590	   .029	  
CD14+CD33+CD163-­‐	   -­‐.354	   .369	   .843	   .542	   -­‐.474	  
CD14+CD33-­‐CD163+	   -­‐.014	   -­‐.018	   -­‐.735	   .192	   .011	  
CD14+CD33+CD163+	   -­‐.022	   .206	   .152	   .391	   .853	  
CD14-­‐CD33+CD163-­‐	   -­‐.217	   .004	   .755	   -­‐.872	   .654	  
CD14-­‐CD33+CD163+	   -­‐.256	   .065	   .729	   -­‐.675	   .719	  
CD14-­‐CD33-­‐CD163+	   -­‐.079	   -­‐.923	   -­‐.043	   .449	   .120	  
IL-­‐6R	  	   	  	   .000	   -­‐.820	   .335	   -­‐.309	  
pSTAT3	  	   .820	   .869	   	  	   .990	   -­‐.953	  
IL-­‐6	  	   .335	   .698	   .990	   	  	   -­‐.230	  
Stroma	   	  	   	  	   	  	   	  	   	  	  
CD14+CD33-­‐CD163-­‐	   -­‐.022	   .844	   -­‐.119	   -­‐.356	   .486	  
CD14+CD33+CD163-­‐	   -­‐.357	   -­‐.581	   -­‐.256	   -­‐.439	   .658	  
CD14+CD33-­‐CD163+	   -­‐.084	   -­‐.523	   -­‐.248	   .552	   .750	  
CD14+CD33+CD163+	   -­‐.027	   -­‐.832	   -­‐.985	   .903	   .954	  
CD14-­‐CD33+CD163-­‐	   .817	   .048	   -­‐.857	   .189	   -­‐.895	  
CD14-­‐CD33+CD163+	   -­‐.288	   .226	   .752	   -­‐.577	   .725	  
CD14-­‐CD33-­‐CD163+	   -­‐.577	   .144	   -­‐.005	   -­‐.572	   -­‐.909	  
IL-­‐6R	  	   .000	   	  	   .869	   .698	   -­‐.466	  
IL-­‐6	  	   -­‐.309	   -­‐.230	   -­‐.953	   .332	   	  	  
Tumor	  epithelium	   	   	   	   	   	  
CD14+CD163-­‐	   -­‐.081	   -­‐.626	   .601	   .626	   .273	  
CD14+CD163+	   -­‐.023	   -­‐.437	   -­‐.797	   .684	   .162	  
CD14-­‐CD163+	   -­‐.265	   .505	   -­‐.429	   .831	   .282	  
CD33+	   -­‐.096	   .048	   .568	   -­‐.756	   -­‐.928	  
CD33-­‐	   -­‐.003	   -­‐.178	   -­‐.317	   .280	   .007	  
Stroma	   	   	   	   	   	  
CD14+CD163-­‐	   -­‐.044	   -­‐.633	   .497	   -­‐.118	   -­‐.549	  
CD14+CD163+	   -­‐.012	   -­‐.880	   -­‐.342	   -­‐.498	   -­‐.499	  
CD14-­‐CD163+	   -­‐.614	   .136	   -­‐.737	   -­‐.317	   -­‐.873	  
CD33+	   -­‐.088	   .733	   -­‐.795	   .370	   -­‐.756	  
CD33-­‐	   -­‐.161	   -­‐.568	   -­‐.412	   -­‐.636	   -­‐.034	  
1Different	  myeloid	  subsets	  were	  identified	  based	  on	  the	  expression	  of	  CD14,	  
CD33,	  and	  CD163	  
2P-­‐values	  are	  given,	  bold	  signifies	  values	  that	  were	  considered	  a	  significant	  
correlation	  if	  p	  <0.05.	  –	  reflects	  negative	  correlation.	  
R-­‐value	  is	  depicted	  in	  Supplementary	  Table	  S3.	  








Figure 1: Representative staining patterns for i) immunohistochemistry: A) tumor core not expressing IL-6 
B) tumor positive for IL-6 C) Magnification of area with IL-6 producing cells D) stroma expressing IL-6 E) low 
expression of IL-6 receptor F) medium expression IL-6 receptor G) high expression of IL-6 receptor H) negative 
for pSTAT3 I) pSTAT3 expressing tumor J) Magnification quadrangle area of Figure 1I. And ii) immunofluores-
cent staining patterns: K) merged image L) Magnification quadrangle area of Figure 1K M) Black and white 
image N) CD14 staining pattern O) CD33 staining pattern P) CD163 staining pattern.








	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Table	  2C	  	  Cellular	  distribution	  of	  m










































































































































































































































































































































































































































































































































































































































































































































































































































































































































Infiltration of myeloid cell populations
 In order to evaluate the presence of myeloid cells in EOC, we quantified 
tumor tissues for macrophages (CD14), their maturation status (CD33) and their po-
larization (M2; CD163) (Figure 1). CD14 is a specific monocyte/macrophage marker, 
although it can also be found on subsets of dendritic cells (26). CD33 is expressed on 
non-terminally differentiated myeloid cells (27) and CD163 is linked to macrophage 
anti-inflammatory functions (26,28,29). The cellular distribution of these myeloid 
cell populations in tumor epithelium and stroma is depicted in Table 2C. In gen-
eral, tumors displayed a suppressive microenvironment as indicated by the high 
numbers of CD163-positive cells present. The stroma was most densely infiltrated 
with myeloid cells. The most abundant cell populations were CD14+CD33-CD163+, 
CD14+CD33+CD163+, and CD14-CD33-CD163+, both in tumor and in stroma.
 There was a correlation between the density of the different cell types that 
infiltrated the tumor epithelium and the stroma (p<0.001) in that having a large 
number of a certain cell type was associated with high numbers of other cell types 
infiltrating the tumor (Supplementary Table S2). Importantly, the distribution of 
the different subtypes of myeloid cells followed the same distribution pattern for 
serous, mucinous and endometrioid tumors. There were no overt differences in the 
number of infiltrating myeloid cells, except that intraepithelial CD14+CD33+CD163+ 
cells were virtually not present in the mucinous subtype when compared to se-
rous and endometrioid tumors (p=0.021). The same trend was observed for CD14-
CD33+CD163+ cells (p=0.063). Furthermore, division of the patients on the basis 
of early and late stage disease revealed a trend for more stromal infiltration with 
CD14-CD33+CD163+ cells in early stage cancer (p=0.063). Thus the distribution and 
number of all myeloid cell populations were grossly comparable among the differ-
ent histological subtypes and among early or late stage tumors. Therefore, subse-
quent analyses on myeloid cells were performed using the entire cohort as one 
group.
 
Tumor expressed IL-6R correlates with a less dense infiltration of mature 
macrophages
 The data from the whole cohort was used in our subsequent analyses to de-
termine the correlation between the expression of IL-6 or pSTAT3 and the influx of 
myeloid cells, as the expression of these two proteins was not related to a specific 
histological subtype. Table 2B shows that high expression of IL-6 in the tumor stro-
ma was positively correlated with the influx of CD14+CD33-CD163- cells (p=0.029) 
and CD14+CD33-CD163+ cells (p=0.011). We analyzed the correlation between all 
mature (CD33-negative) myeloid cell populations and found a positive correlation 
with IL-6 expression in the tumor stroma (p=0.007) (Table 2B). The expression of 
IL-6 by the tumor epithelium was not significantly correlated with the presence of 
myeloid cells. The expression of pSTAT3 by tumor cells was related to a lower infil-
tration with CD14-CD33-CD163+ cells in tumor epithelium and stroma (p=0.043, 









 In addition, we analyzed the expression of the IL-6R with infiltration of dif-
ferent types of myeloid cells, taking into account the differences found in expres-
sion of the IL-6R in the different histological subtypes. First we analyzed all subtypes 
together, and found that a high expression of IL-6R by the tumor epithelium was 
correlated with the infiltration of low numbers of different types of intraepithelial 
macrophages, reflected by CD14+CD33-CD163-, CD14+CD33-CD163+ and CD14+C-
D33+CD163+ (p<0.001, p=0.014, p=0.022 respectively) and low numbers of stromal 
CD14+CD33-CD163- and CD14+CD33+CD163+ cells (p=0.022, p=0.027 respective-
ly, Table 2B). A high expression of IL-6R in stroma was negatively correlated with 
intraepithelial infiltration by mature macrophages CD14+CD33-CD163+ (p=0.018), 
but was positively correlated with a dense influx of immature myeloid cell popula-
tions represented by CD14-CD33+CD163- (p=0.004). This same pattern was seen in 
the stroma (Table 2B).
 Then we analyzed the different histological subtypes by comparing the 
number of the different stromal or intraepithelial myeloid cells in tumors with low 
or no expression of IL-6R versus the tumors with a high expression of IL-6R. The 
tumors of serous origin with high expression of IL-6R displayed a lower infiltration 
with intraepithelial and stromal CD14+CD33-CD163- cells, CD14+CD33-CD163+ 
cells and CD14+CD33+CD163+ cells when compared to serous tumors with no or 
low IL-6R expression (Supplementary Table S4). The number of patients with a 
tumor of mucinous or endometrioid origin stained for all markers was much low-
er than the number of serous tumors, however, clearly the tumors with a low IL-
6R expression displayed high numbers of stromal CD14+CD33-CD163+ cells and 
CD14+CD33+CD163+ cells, while these numbers were strongly reduced in tumors 
with high IL-6R expression (Supplementary Table S4). Finally, late stage tumors 
with high expression of IL-6R were also infiltrated by less intraepithelial and stromal 
CD14+CD33-CD163-, CD14+CD33-CD163+ and CD14+CD33+CD163+ cells as com-
pared to their counterparts with a low expression of IL-6R (Supplementary Table 
S4).
 Then, the correlation between all mature (CD33-negative) intraepithelial 
myeloid cell populations and IL-6R expression of the tumor was analyzed. This con-
firmed that a dense infiltration with mature intraepithelial myeloid cells was spe-
cifically detected in tumors with low/no IL-6R expression while their intraepithelial 
numbers were low in tumors with a strong IL-6R expression (p=0.003; Table 2B). Di-
vided per stage, more mature myeloid cells (CD33-) were seen in late stage patients 
(p=0.013, data not shown).
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Figure 2: Kaplan Meier survival analysis 
for disease-specific survival (DSS), differ-
ences between groups were analyzed by 
Log Rank test. A) IL-6 expression in tu-
mor epithelium is a predictor of shorter 
survival (p=0.034). B) High expression of 
the IL-6 receptor in tumor epithelium is 
associated with a longer DSS (p=0.010). 
C) IL-6R expression analyzed for early and 
late stage disease. In early stage patients, 
no difference in DSS was detected for the 
different expression groups (p=0.239). In 
late stage patients, a high expression of 
the IL-6 receptor in tumor epithelium is 
associated with a longer DSS (p=0.045). 
D) Patients having a low infiltration of 
CD33- cells (lowest tertile) show an im-
proved survival (p=0.017) as compared 
to patients with a higher infiltration of 
these cell types. E) No survival differenc-
es were detected when CD33- infiltration 



































































































































































































































































































































































































































































































































































































































Univariate analysis of disease-specific survival
 The influence of each marker on disease-specific survival (DSS) was deter-
mined by constructing Kaplan Meier curves, and differences between groups were 
compared by Log Rank test. We found that epithelial IL-6 expression was correlated 
with a shorter DSS (p=0.034). Interestingly, a longer DSS (p=0.010) was seen in pa-
tients having a high expression of the IL-6R on tumor epithelium (Figure 2). Since 
early stage disease had relatively higher expression of the IL-6R, the Kaplan Meier 
analysis was also split into early and late stage disease. This revealed that the sur-
vival difference was only seen in late stage disease patients (p=0.045; Figure 2). 
There was no survival difference found between the different histological subtypes. 
Further, DSS survival of patients was shorter if patients had a relatively high infil-
tration with CD33- cells in tumor epithelium (p=0.017; Figure 2). Here, no survival 
differences were observed based on stage or histological subtype. Other markers 
were not significantly correlated with DSS in univariate analysis.
Multivariate analysis
 Variables that were significantly associated with DSS in the univariate anal-
yses were entered into a Cox proportional hazards model. The model was adjust-
ed for well-known prognostic parameters and stratified for type of chemotherapy 
(Table 3). In this model, IL-6 expression in tumor epithelium was not an indepen-
dent prognostic marker for survival (p=0.851; HR= 0.940; 95% CI 0.491-1.797). Also 
CD33- infiltration did not show to be an independent prognostic factor (p=0.694; 
HR= 0.998; 95% CI 0.991-1.006). High IL-6R expression in tumor epithelium, howev-
er, was correlated with early stage disease (p=0.035), low-grade tumors (p<0.001; 
data not shown) and non-serous tumors (p=0.032; Table 2A). Importantly, in the 
multivariate analysis including these parameters, IL-6R expression in tumor epithe-
lium was considered to be an independent prognostic marker. High expression was 
associated with a longer disease-specific survival, represented by a hazard ratio of 
0.474 (p=0.011; 95% CI 0.268-0.841).
 
Unsupervised hierarchal clustering based on immune parameters
 Previously we reported the infiltration of these tumors by T cells (9). To 
gain a better insight into the immunological composition of EOC, we constructed a 
heatmap (Figure 3A) containing 76 patients of which data from all previously estab-
lished lymphoid parameters, our current data on myeloid cell populations, and on 
the markers of the IL-6 signaling pathway were available. Unsupervised clustering 
divided the patients into two major groups (A and B) that were both subdivided into 
two groups (A1 and A2, B1 and B2), which could be further subdivided into 6 small-
er groups (A1, A2I, A2II, B1, B2I, and B2II). The Kaplan Meier analysis of the six sub-
groups is shown in Figure 3B. A significant survival difference was found between 
groups B2I and B2II (p= 0.039), with the patients in group B2II displaying a shorter 
survival. Tumors in group B2II showed a dense infiltration of lymphoid (including 








FoxP3+ cells) and myeloid cells. Group B2I on the other hand comprised tumors 
from patients in which the infiltrating myeloid cells were mostly of the CD163-neg-
ative subtype. Furthermore, the tumors in this group displayed dense infiltration 
with CD8+ cells, but low numbers of infiltrating FoxP3+cells.
 These observations led us to hypothesize that the proportion of CD8+ T 
cells and tumor promoting CD163+ myeloid cells (CD8/CD163 ratio) is predictive 
for survival. Figure 3C presents the Kaplan Meier analysis on the CD8/CD163 ratio 
in the group of patients with high lymphocyte infiltration (CD8+ infiltration above 
median). Indeed, this ratio was predictive for survival (p=0.036) and this was inde-
pendent of the stage of disease (data not shown).




















Figure 3 A) A heatmap was created by unsupervised hierarchal clustering of patients based on all known 
immunological parameters. Included were lymphoid and myeloid cell populations and markers of the IL-6 sig-
naling pathway. The changes from the lowest to highest tertile are reflected by a darker color, white boxes are 
missing data. On the X-axis the 76 included patients are depicted, and on the Y-axis all immune parameters 
are indicated. Each column represents the immune profile of one patient. Brackets to the left and along the 
top indicate the unsupervised clustering. B) Kaplan Meier analysis for the disease-specific survival of the six 
subgroups as determined by clustering analysis. A significant survival difference was found between groups 
B2I and B2II (p= 0.039). C) Kaplan Meier survival analysis for disease-specific survival of CD8/CD163 ratio 
lowest tertile versus all other patients in patients with a high lymphocyte infiltrate (above median). Patients 
with a low ratio had significant shorter DSS (p=0.034). Differences were analyzed by Log Rank test. 






















We studied the composition of infiltrating myeloid cells and the expression 
of important mediators in the IL-6 signaling pathway in EOC. In general, ovarian 
tumors pose a hostile environment to immune effector cells, reflected by a dense 
infiltration with suppressive CD163+ types of myeloid cells as shown here and by 
others (29,30). The most abundant intraepithelial and stromal cell populations we 
found were CD14+CD33-CD163+ cells, CD14+CD33+CD163+ cells, and CD14-CD33-
CD163+ cells. Whereas the former two represent M2 macrophages, the latter pop-
ulation is likely to reflect immunosuppressive dendritic cells (DC’s) or DC-derived 
macrophages (29,31). As ovarian cancer refers to five different histological subtypes 
with distinct sites of origin, one can imagine that they have differences in the im-
mune composition as well. Here, however, we show that the distribution pattern of 
all myeloid subtypes was comparable and proportional in the analyzed histological 
subtypes, suggesting that although EOC can originate from different cell types their 
attraction and polarization of myeloid cells does not really differ. There were no 
particular myeloid subpopulations directly correlated with DSS.
The expression of the IL-6R was most often seen in early stage, low grade, 
and non-serous histology, but was also found among serous tumors and late stage 
cancers. A high expression of the IL-6R on epithelial ovarian cancer cells was as-
sociated with a significantly longer DSS, an effect that was specifically seen in late 
stage disease and not among early stage patients who all did very well (Figure 2). 
Importantly, the expression of IL-6R was an independent prognostic marker for an 
improved DSS in a multivariate analysis in which stage, grade, and histology were 
taken into account (p=0.011; 95% CI 0.268-0.841).
Interestingly, tumors with a high expression of the IL-6R displayed a general 
lower number of intraepithelial and stromal myeloid cells than those with low or no 
IL-6R expression. Especially the number of mature (CD33-) myeloid cells was lower 
in tumors with high IL-6R expression. This suggests that the local microenvironment 
of tumors with a high IL-6R expression is less suppressive. Indeed, we observed a 
correlation between low infiltration with mature (CD33-) myeloid cells and longer 
survival. Although IL-6R expression is positively correlated with an influx of imma-
ture CD33+ cells, these are likely to reflect the previously identified inflammatory 
anergic macrophages that, as such, will not contribute to immune suppression (32). 
In one other study of IL-6R expression in ovarian cancer tissue no correlation was 
found between IL-6R expression and survival (17). Here, the expression of IL-6R was 
scored using a different method and the survival was plotted based on the median 
expression. Thereby, the patients with medium and high expression of IL-6R were 
mixed, whereas we found a difference in survival by plotting on basis of high IL-6R 
expression.
Our data suggest that the tumors with no to low expression of IL-6R do not 
require IL-6R receptor signaling for their growth and that tumors still expressing IL-








6R depend on IL-6 produced outside the tumor cell. A possible explanation for the 
lack of staining could be that the more progressive tumors express a differentially 
spliced isoform of IL-6R that lacks the transmembrane (33) and as such will not be 
detected. However, we envision that once tumors have an autocrine production of 
IL-6, and can provide IL-6 needed for growth, signaling, and immunosuppressive 
actions, the receptor might be lost, and tumors may become more resistant (34,35). 
Our data corroborate this hypothesis, since tumor expression of IL-6 and IL-6R are 
not correlated.
A high expression of IL-6 within the tumor is correlated with a shorter DSS 
(p=0.034), albeit that IL-6 expression was not an independent prognostic factor. This 
observation sustains previous notions that the level of serum IL-6 in EOC patients 
correlates with poor survival (36–38). Surprisingly, the myeloid cell infiltration of 
tumors with high IL-6 expression was the opposite of that found in tumors with high 
IL-6R expression. Tumors with high IL-6 expression displayed a dense infiltration 
with CD14+CD33-CD163- cells and CD14+CD33-CD163+ cells, specifically the ma-
ture (CD33-) type of myeloid cells. Our observation that the expression of IL-6 was 
correlated with the presence of CD14+CD33-CD163- cells, potentially reflecting re-
cent infiltrated monocytes or M1 macrophages (24), is somewhat counterintuitive. 
However, as the number of these tumor-infiltrating cells was generally low when 
compared to other cancer types (24), and is directly correlated to co-infiltration 
with much larger quantities of suppressive CD33-CD163+ cells, this association is 
more likely to reflect that in essence IL-6 expressing tumors induce a hostile tumor 
immune environment. This scenario corresponds also with our observations that 
IL-6 producing ovarian cancer cells can polarize the differentiation of monocytes 
towards M2 macrophages (18). A high level of IL-6 in the tumor microenvironment 
may attract and differentiate macrophages into subtypes that in their turn produce 
more IL-6, creating an immunosuppressive environment. Recently, Reinartz et al 
(39). defined a subgroup of ovarian cancer patients with a poor clinical outcome, 
these patients displayed a high CD163 expression and high IL-6 levels in ascites.
In order to obtain a better understanding of the immune composition of 
these tumors, we performed an unsupervised clustering on all known immune pa-
rameters and IL-6 pathway markers. This revealed roughly two types of tumor envi-
ronments with a difference in survival (Figure 3). We can distinguish (i) a tumor re-
jecting environment (B2I) with a high infiltration of cytotoxic CD8+ T cells and fewer 
M2 macrophages and FoxP3+ cells (T regs), associated with a favorable clinical out-
come and (ii) an immunosuppressive environment (B2II), with high infiltration of T 
regs and M2 macrophages, and a low infiltration of CD8+ cells, associated with a 
worse prognosis. Interestingly, in a recent study it was shown that such a compo-
sition of the tumor infiltrating immune cells in ovarian cancer is related to tumor 
expression of HOXA9 (40). Previously, we and others have shown that the CD8/T reg 
ratio was predictive for survival in EOC (9,36,41). The constructed heatmap led us 
to hypothesize that in tumors highly infiltrated with CD8+ cells, the positive effect 








of CD8+ T cells may be counteracted by suppressive CD163+ myeloid cells and thus 
influence survival. Indeed, the CD8/CD163 ratio in highly infiltrated tumors was a 
predictive marker for DSS (p=0.036), confirming the role of CD163+ cells as an im-
munosuppressive population and implying that patients may benefit from therapy 
that either depletes M2 macrophages or switches polarization of CD163+ cells to-
wards M1 macrophages.
In summary, we found that IL-6R expression on tumor cells is an indepen-
dent predictive factor for improved outcome and is associated with a low infiltra-
tion of mature myeloid cells. Furthermore, we showed that IL-6 is associated with 
a high density of mature myeloid cells and is correlated with a worse prognosis. In 
addition, a high density of M2 myeloid cells displayed a negative impact on CD8 
T cells; in patients with a high lymphocyte infiltration, the CD8/CD163 ratio is a 
positive predictor of survival. Based on these data we can distinguish two types 
of tumors based on IL-6, IL-6R, and immune infiltration. The first group of patients 
has tumors with a high expression of IL-6R and a low infiltration by mature myeloid 
cells. These patients have a good survival, suggesting that determination of IL-6R 
expression might be useful as a prognostic marker. The second group consists of 
patients of which tumors do not display the IL-6R, but have a high expression of IL-6, 
and are densely infiltrated with mature CD163+ myeloid cells. These patients have a 
worse prognosis and, potentially, blocking of the IL-6R may prevent differentiation 
of monocytes into M2 macrophages (18) and prevent tumor progression.
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Supplementary	  Table	  S1:	  tumor	  subtypes	  subdivided	  for	  stage	  	  
	  
serous	   mucinous	   endometrioid	  
early	   9	  (11.3%)	   14	  (66.7%)	   14	  (60.9%)	  
late	   71	  (88.7%)	   7	  (33.3%)	   9	  (39.1%)	  
total	   80	   21	   23	  
	  
Supplementary	  Table	  S2	  Correlation	  between	  different	  myeloid	  cell	  subsets,	  based	  on	  expression	  of	  CD14,	  CD33,	  and	  CD163	  
	  	  















































































































































Tumor	  epithelium	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
CD14+CD33-­‐CD163-­‐	   	  	   .613	   .000	   .000	   .633	   .456	   .002	   	   .000	   .422	   .447	   .096	   .919	   .949	   .295	   	  	  
CD14+CD33+CD163-­‐	  
	  
	  	   .553	   .002	   .003	   .014	   .055	   	   .434	   .069	   .128	   .292	   .298	   .687	   .180	   	  	  
CD14+CD33-­‐CD163+	  
	   	  
	  	   .000	   .173	   .292	   .000	   	   .001	   .128	   .006	   .924	   .208	   .308	   .305	   	  	  
CD14+CD33+CD163+	  
	   	   	  
	  	   .163	   .004	   .005	   	   .004	   .507	   .815	   .030	   .312	   .048	   .208	   	  	  
CD14-­‐CD33+CD163-­‐	  
	   	   	   	  
	  	   .000	   .084	   	   .358	   .183	   .363	   .009	   .000	   .001	   .341	   	  	  
CD14-­‐CD33+CD163+	  
	   	   	   	   	  
	  	   .014	   	   .441	   .151	   .903	   .003	   .001	   .000	   .113	   	  	  
CD14-­‐CD33-­‐CD163+	  
	   	   	   	   	   	  
	  	   	   .034	   .484	   .250	   .344	   .787	   .378	   .004	   	  	  
Stroma	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
CD14+CD33-­‐CD163-­‐	  
	   	   	   	   	   	   	  
	   	  	   .007	   .000	   .000	   .001	   .002	   .000	   	  	  
CD14+CD33+CD163-­‐	  
	   	   	   	   	   	   	  
	   	  	   	  	   .389	   .000	   .001	   .008	   .228	   	  	  
CD14+CD33-­‐CD163+	  
	   	   	   	   	   	   	  
	   	  	  
	  
	  	   .001	   .848	   .511	   .000	   	  	  
CD14+CD33+CD163+	  
	   	   	   	   	   	   	  
	   	  	  
	   	  
	  	   .000	   .000	   .001	   	  	  
CD14-­‐CD33+CD163-­‐	  
	   	   	   	   	   	   	  
	   	  	  
	   	   	  
	  	   .000	   .008	   	  	  
CD14-­‐CD33+CD163+	  
	   	   	   	   	   	   	  
	   	  	  
	   	   	   	  
	  	   .000	   	  	  
CD14-­‐CD33-­‐CD163+	   	   	   	   	   	   	   	   	   	  	   	   	   	   	   	  	   	  	   	  	  
1Different	  myeloid	  subsets	  were	  identified	  based	  on	  the	  expression	  of	  CD14,	  CD33,	  and	  CD163	  
2p-­‐values	  are	  given,	  bold	  signifies	  values	  that	  were	  considered	  a	  significant	  correlation	  p	  <0.05.	  –	  reflects	  negative	  correlation.	   	  
	  































Supplementary	  Table	  S3	  Correlation	  coefficient	  of	  markers	  of	  IL-­‐6	  signaling	  








































Tumor	  epithelium1,2	   	  	   	  	   	  	   	  	   	  	  
CD14+CD33-­‐CD163-­‐	   -­‐.428	   -­‐.224	   -­‐.091	   -­‐.065	   .297	  
CD14+CD33+CD163-­‐	   -­‐.116	   .068	   .025	   .074	   -­‐.100	  
CD14+CD33-­‐CD163+	   -­‐.300	   -­‐.324	   .043	   .158	   .342	  
CD14+CD33+CD163+	   -­‐.283	   .187	   .181	   .104	   .026	  
CD14-­‐CD33+CD163-­‐	   -­‐.154	   .303	   -­‐.040	   -­‐.020	   .062	  
CD14-­‐CD33+CD163+	   -­‐.142	   .328	   .044	   -­‐.051	   .050	  
CD14-­‐CD33-­‐CD163+	   -­‐.218	   -­‐.084	   -­‐.253	   .092	   .214	  
IL-­‐6R	  	   	   .450	   -­‐.024	   .096	   -­‐.123	  
pSTAT3	  	   -­‐.024	   .023	   	   .001	   -­‐.008	  
IL-­‐6	  	   .096	   .048	   .001	   	   .115	  
Stroma	   	   	   	   	   	  
CD14+CD33-­‐CD163-­‐	   -­‐.288	   -­‐.080	   -­‐.202	   -­‐.115	   -­‐.100	  
CD14+CD33+CD163-­‐	   -­‐.118	   -­‐.080	   -­‐.148	   -­‐.096	   .058	  
CD14+CD33-­‐CD163+	   -­‐.219	   -­‐.113	   -­‐.150	   .074	   .046	  
CD14+CD33+CD163+	   -­‐.279	   .019	   -­‐.002	   .015	   .008	  
CD14-­‐CD33+CD163-­‐	   .030	   .180	   -­‐024	   .163	   -­‐.019	  
CD14-­‐CD33+CD163+	   -­‐.136	   .197	   .041	   -­‐.069	   .051	  
CD14-­‐CD33-­‐CD163+	   -­‐.072	   .175	   -­‐.354	   -­‐.070	   -­‐.016	  
IL-­‐6R	  	   .450	   	   .023	   .048	   -­‐.144	  
IL-­‐6	  	   -­‐.123	   -­‐.144	   -­‐.008	   .115	   	  
Tumor	  epithelium	   	   	   	   	   	  
CD14+CD163-­‐	   -­‐.216	   -­‐.072	   .067	   .059	   .152	  
CD14+CD163+	   -­‐.279	   -­‐.115	   -­‐.033	   .050	   .193	  
CD14-­‐CD163+	   -­‐.139	   .099	   -­‐.101	   .026	   .149	  
CD33+	   -­‐.206	   .321	   .073	   -­‐.012	   -­‐.013	  
CD33-­‐	   -­‐.359	   -­‐.198	   -­‐.127	   .131	   .366	  
Stroma	   	   	   	   	   	  
CD14+CD163-­‐	   -­‐.254	   -­‐.071	   .089	   -­‐.193	   -­‐.086	  
CD14+CD163+	   -­‐.315	   -­‐.023	   -­‐.124	   -­‐.084	   -­‐.097	  
CD14-­‐CD163+	   -­‐.065	   .221	   -­‐.044	   -­‐.124	   -­‐.032	  
CD33+	   -­‐.088	   .095	   -­‐.034	   -­‐.038	   -­‐.045	  
CD33-­‐	   -­‐.345	   -­‐.135	   -­‐.206	   .040	   -­‐.568	  
1Different	  myeloid	  subsets	  were	  identified	  based	  on	  the	  expression	  of	  CD14,	  
CD33,	  and	  CD163	  
2correlation	  coefficients,	  bold	  signifies	  values	  that	  were	  considered	  a	  	  
significant	  correlation	  p	  <0.05.	  –	  reflects	  negative	  correlation	  








Low/no Medium	   High	   Low/no	   Medium	   High	   Low/no	   Medium	   High	  
	  expression expression expression expression expression expression expression expression expression
CD14+CD33-­‐CD163-­‐ 62,92 6,56 0 -­‐.000 91,32 81,44 10,41 -­‐.867 0 0 18,33 -­‐.291
CD14+CD33+CD163-­‐ 32,89 42,45 3,16 -­‐.334 106,54 18,3 34,63 .736 0 27,44 6,99 -­‐.785
CD14+CD33-­‐CD163+ 171,3 106,96 87,35 -­‐.415 296,8 310,62 37,48 -­‐.741 394,74 171,43 64 -­‐.021
CD14+CD33+CD163+ 199,47 98,37 45,1 -­‐.147 426,18 81,44 49,46 .736 11,96 59,05 30,41 -­‐.869
CD14-­‐CD33+CD163-­‐ 8,1 19,18 9,2 -­‐.868 7,61 4,81 42,21 .175 0 9,04 3,5 .837
CD14-­‐CD33+CD163+ 63,94 52,87 11,77 -­‐.176 60,88 6,82 84,76 .461 0 6,32 12,24 .785
CD14-­‐CD33-­‐CD163+ 145,31 95,22 179,46 -­‐.612 318,62 270,93 87,66 -­‐.222 107,66 52,15 156,04 .869
Low/no	   Medium	   High	   Low/no	   Medium	   High	  
expression expression expression expression expression expression
CD14+CD33-­‐CD163-­‐ 0 63,04 12,63 -­‐.268 78,38 6,55 0 -­‐.478
CD14+CD33+CD163-­‐ 0 65,55 15,04 .236 52,96 34,23 4,73 .483
CD14+CD33-­‐CD163+ 197,37 202,19 52,44 -­‐.609 215,96 122,69 107,18 -­‐.147
CD14+CD33+CD163+ 5,98 276,42 35,3 .935 282,15 88,26 56,82 .131
CD14-­‐CD33+CD163-­‐ 0 84,8 17,26 .181 12,74 11,41 9,47 .539
CD14-­‐CD33+CD163+ 0 171,59 34,73 .832 84,07 35,44 16,57 .154
CD14-­‐CD33-­‐CD163+ 189,8 252,38 139,75 .734 174,41 86,86 171,66 .915
Depicted	  are	  the	  mean	  numbers	  of	  cells	  per	  mm2	  in	  tumor	  epithelium.	  1Mann	  Whitney	  U	  test,	  Bonferroni	  correction
p-­‐value1 p-­‐value1
Early	  stage Late	  stage
p-­‐value1
Supplementary	  Table	  S4B.	  Cellular	  distribution	  of	  myeloid	  cell	  populations	  in	  tumor	  stroma	  and	  correlation	  with	  IL-­‐6R	  in	  tumor	  epithelium	  divided	  per	  subtype	  and	  stage.	  
Serous Endometrioid Mucinous
p-­‐value1 p-­‐value1
